Prof. Fabien Gosselet

Blood-brain barrier Laboratory, EA2465

Faculty Jean Perrin, Artois University

Brief CV

Fabien Gosselet graduated in Biology and received a PhD in Cancerology (2006) from the Medicine faculty of Paris XI. He completed his education at the bloodbrain barrier laboratory (BBB-Lab), located in Lens (France), as post-doctoral fellowship. In 2008 he obtained an assistant Professor position at the BBB-Lab and is full Professor since 2016. He was the co-head of the BBB-lab from 2013 to 2014. Since 2015, he is director of the BBB-Lab. The 30 members of his lab use housemade in vitro BBB models not only for investigating BBB physiology and its role in neurodegenerative diseases (Alzheimer’s and Parkinson diseases, stroke, brain tumor metastasis,…) but also for improving drug delivery and for providing data in pharmaco-toxicological field and to pharmaceutical companies. Since its creation in 2000, the BBB-lab actively contributed to several FP6 (AcuteTox) and FP7 (Predict IV, Eustroke) programs and is currently involved in three H2020 consortia (BtRAIN, In3, Nanostem) and two European projects (DiaSyn and SnowBall). In 2014, the BBB-lab developed and patented a human in vitro BBB models consisting to co-cultivate human umbilical cord blood stem cells with brain pericytes. This model is now transferred into 16 European Labs. 

Scientific production : 25 research articles and 7 review articles in international peer reviewed journals, 2 editorial letters, 1 book chapters. Participation in more than 30 international and national conferences among which 6 as invited speaker. Editorial board of 4 journals. More than 50 reviewing for peer-reviewed journals, associations and for national/international agencies.
Bibliometric data: 614citations, H-factor=14 Other: Participation in more than 15 National and collaborative International research projects, 7 as IP . 3 contracts with private companies. Supervision of 5 PhD Theses (2 finalized).

Role in the project

Function of endothelial cells and brain pericytes, BBB modelling and physiology.

Team qualification in the field of proposal

The group is recognized as world expert in the modelling of the BBB. Indeed, this team has carried out pioneering work in establishing an animal model of the BBB which has been used to investigate BBB physiology and distribution of compounds for pharmaceutical industries. New BBB models have also been used to better characterize the BBB in stroke (FP7 Eustroke and EU Joint programme). In 2013, the team set up a human in vitro model of the BBB consisting to cultivate CD34+-cells with brain pericytes which is now widely used for mechanistic studies and for permeability screenings. Currently his team is involved in 3 different Innovative Training Networks, 1 Euronanomed (DIASYN) and 1 JPCoFUND European projects. Two permanent scientists (1 professor and 1 research engineer) and 1 post-doc will be implicated in the  evaluation of the effects of secretome and nanocapsules at the BBB level.

List of relevant publications

1) Hachem M, Geloen A, ..., Fenart L, Gosselet F, Da Silva P, Breton G, Lagarde M, Picq M, Bernoud-Hubac N. Efficient Docosahexaenoic Acid Uptake by the Brain from a Structured Phospholipid. Mol Neurobiol. 2016 Jul;53(5):3205-15.


2) Merino-Zamorano C, Fernández-de Retana S, Montañola A, Batlle A, Saint-Pol J, Mysiorek C, Gosselet F, Montaner J, Hernández-Guillamon M. Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier. J Alzheimers Dis. 2016 May 25;53(2):677-91.


3) Schultz L, Zurich MG, Culot M, da Costa A, Landry C, Bellwon P, Kristl T, Hormann K, Ruzek S, Aiche S, Reinert K, Bielow C, Gosselet F, …, Bal-Price A. Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models. Toxicol In Vitro. 2015 25;30(1 Pt A):138-65.


4) Kuntz M, Candela P, Saint-Pol J, Lamartiniere Y, Boucau MC, Sevin E, Fenart L, Gosselet F. Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to- Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier. J Alzheimers Dis. 2015 Oct 1;48(3):849-62.


5) Saint-Pol J, Candela P, Boucau MC, Fenart L, Gosselet F. Oxysterols decrease apical-to-basolateral transport of As peptides via an ABCB1-mediated process in an in vitro Blood-brain barrier model constituted of bovine brain capillary endothelial cells. Brain Res. 2013;1517:1-15.

Team members

Rodrigo Azevedo

Post-doc